Our team has tried to address some of these challenges by assessing the impact of different CKD-MBD treatment ‘actions’ rather than static parameters, such as the level of calcium, phosphorus or PTH, or use of a specific medication [51]. This evidence concerns the gene PTH and Marchiafava-Bignami disease.